- Home
- POWW vs RNA Comparison
POWW vs RNA Comparison
Compare POWW & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POWW | RNA |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | 63 | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.6M | 222.5M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | POWW | RNA |
|---|---|---|
| Price | $2.13 | $12.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $2.40 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 504.8K | 117.7K |
| Earning Date | 02-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.56 | $88.12 |
| Revenue Next Year | $0.50 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $11.13 |
| 52 Week High | $2.60 | $73.06 |
Technical Indicators
Market Signals| Indicator | POWW | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 51.20 |
| Support Level | $1.94 | $11.95 |
| Resistance Level | $2.23 | $14.05 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 45.10 | 80.33 |
Price Performance
Historical ComparisonAbout POWW AMMO Inc.
Outdoor Holding Co the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketplace segment consists of the GunBroker e-commerce marketplace. The company generates the majority of its revenue from the Ammunition segment.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.